{"url_path":"/sec/tpst/8-k/2026-07-22/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-312391-index.html","accession_number":"0001193125-26-312391","cik":"0001544227","ticker":"TPST","issuer_name":"Tempest Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-312391-index.html","primary_entity_key":"0001544227","primary_entity_name":"Tempest Therapeutics, Inc."},"word_count":101,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits\n\n(d) Exhibits\n\n \n\n10.1\n  \n[Product Development and Investigator-Initiated Trial (IIT) Collaboration Agreement, dated July 17, 2026, by and between Tempest Therapeutics, Inc. and Heibei Senlang Biotechnology Co., Ltd.](d107304dex101.htm)\n\n99.1\n  \n[Press Release, dated July 21, 2026](d107304dex991.htm)\n\n104\n  \nCover Page Interactive Data File (formatted in Inline XBRL)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nTEMPEST THERAPEUTICS, INC.\n\nDate: July 22, 2026\n \n\n \nBy:\n \n\n/s/ Matthew Angel\n\n \n\n \nName:\n \nMatthew Angel\n\n \n\n \nTitle:\n \nPresident and Chief Executive Officer"}